Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | CCND1 | P24385 | 3/20 | 0.49 |
| ▸ | PRKCB | P05771 | 3/20 | 0.49 |
| ▸ | PRKCA | P17252 | 3/20 | 0.49 |
| ▸ | PRKCH | P24723 | 3/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.49 |
| ▸ | PRKCG | P05129 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | PRKACG | P22612 | 2/20 | 0.49 |
| ▸ | PRKACB | P22694 | 2/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871069 | 0.84 | ROCK2 (0.58) | CDK4CCND1PRKCBCDK5CDK5R1 | |
| SCHEMBL6997570 | 0.79 | SIRT2 (0.49) | MEN1KMT2AGSK3BSIRT2KDM4E | |
| SCHEMBL5686050 | 0.77 | CAMK2D (0.57) | CDK4CCND1PRKCBPRKCAPRKCH | |
| SCHEMBL6860285 | 0.74 | PRKACA (0.47) | CDK4CCND1PRKCBPRKCAPRKCH | |
| SCHEMBL6867314 | 0.73 | SMN1; SMN2 (0.47) | CDK4CCND1PRKCBPRKCAPRKCH | |
| SCHEMBL11602909 | 0.72 | CDK4 (0.61) | CDK4CCND1PRKCBPRKCAPRKCH | |
| SCHEMBL484701 | 0.71 | MAP3K11 (0.55) | CDK4CCND1PRKCBPRKCAPRKCH | |
| SCHEMBL15797114 | 0.71 | PRKCB (0.54) | CDK4CCND1PRKCBPRKCAPRKCH | |
| SCHEMBL20243386 | 0.71 | CAMK2D (0.55) | CDK4CCND1PRKCBPRKCAPRKCH | |
| SCHEMBL29940783 | 0.70 | CA1 (0.50) | CDK4CCND1PRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | CDK4 22/4885CCND1 52/4885PRKCB 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.